Related Experiment Video
Updated: Feb 7, 2026

Using Laser Scanning Microscopy to Determine Electromigration in Molybdenum Disilicide
Published on: May 23, 2025
Molybdenum bupropion combined neurotoxicity in rats
A M Helaly1, Naglaa Mokhtar2, Alaa El-Din L Firgany3
1Forensic and Clinical Toxicology Department, Egypt; Faculty of Medicine, Yarmouk University, Jordan.
Abstract:
Heavy metal toxicity is a common foodborne problem in Egypt, especially in combination. Molybdenum toxicity has been studied as a model of the heavy metal toxicity. Molybdenum could promote toxicity via oxidative-inflammatory mechanisms. Bupropion is a well-known antidepressant that has anti-oxidant mechanisms. It exerts a cytoprotective action against molybdenum induced metal toxicity. The aim of the study is to evaluate the effects of combined bupropion and molybdenum in a toxic animal model. The results showed that the combination of bupropion and high doses of molybdenum was extremely toxic with an evident animal fatality. Bupropion showed a clear anti-oxidant/anti-inflammatory profile detected by the ELISA assay of malondialdehyde (MDA), reduced glutathione, and interleukin -6 (IL-6), and real-time gene expression of nuclear factor erythroid 2-related factor 2 (Nrf2) and tumor necrosis factor-α (TNF-α). The immunohistochemistry of nuclear factor Kappa Beta (NF-κB) showed that bupropion reduced the inflammatory response induced by the molybdenum neurotoxicity. Despite the improved laboratory profile, the animals were extremely intoxicated with recorded fatalities raising the question about other pathways and mechanisms explaining the drug metal interaction. Furthermore, Bupropion even in normal doses was toxic to the animals. Choroid plexus hyperplasia was reported in the histological examination of the animal brain loaded with bupropion, and choroid plexus papilloma was recorded in the combined drug metal group. More wide-scale studies are needed to verify the safety of the current antidepressant medications for the long-term therapy. It is important to focus on drug metal interaction as a possible cause of neuropathology.
Insights
Combining the antidepressant bupropion with molybdenum, a heavy metal, proved highly toxic in animal models, causing significant fatalities. Bupropion demonstrated antioxidant and anti-inflammatory effects, but paradoxically, the combination led to severe intoxication and brain abnormalities.
Area of Science:
- Toxicology
- Neuroscience
- Pharmacology
Background:
- Heavy metal toxicity, particularly from molybdenum, poses a significant foodborne health risk in Egypt.
- Molybdenum toxicity is understood to operate through oxidative-inflammatory pathways.
- Bupropion, an antidepressant, possesses antioxidant properties and may offer protection against certain toxicities.
Purpose of the Study:
- To investigate the toxicological effects of combining bupropion with molybdenum in an animal model.
- To assess the potential cytoprotective or synergistic toxic effects of this drug-metal interaction.
Main Methods:
- Administration of bupropion and varying doses of molybdenum to a toxic animal model.
- Evaluation of oxidative stress and inflammation markers using ELISA assays for malondialdehyde (MDA), reduced glutathione, and interleukin-6 (IL-6).
- Analysis of gene expression for nuclear factor erythroid 2-related factor 2 (Nrf2) and tumor necrosis factor-α (TNF-α) via real-time PCR.
- Immunohistochemical examination of nuclear factor Kappa Beta (NF-κB) and histological analysis of brain tissue.
Main Results:
- The combination of bupropion and high-dose molybdenum resulted in extreme toxicity and significant animal mortality.
- Bupropion exhibited antioxidant and anti-inflammatory effects, reducing MDA and IL-6 levels and modulating Nrf2 and TNF-α gene expression.
- Bupropion mitigated molybdenum-induced neuroinflammation, as evidenced by reduced NF-κB activity.
- Histological examination revealed bupropion-induced choroid plexus hyperplasia and combined bupropion-molybdenum-induced choroid plexus papilloma.
Conclusions:
- The combination of bupropion and molybdenum is highly toxic, leading to severe intoxication and fatalities, despite bupropion's observed anti-inflammatory and antioxidant effects.
- Bupropion itself demonstrated toxicity at normal doses, causing choroid plexus hyperplasia.
- The study highlights potential risks of drug-metal interactions, particularly concerning neuropathology and the long-term safety of antidepressants.
- Further extensive research is crucial to understand these complex interactions and ensure the safety of antidepressant medications.
Related Concept Videos
Impedance Combination
Combination Of Resistors
Combining Functions
Stresses under Combined Loadings
The process begins by slicing the tube at critical points and analyzing the internal forces and stress components at these sections, focusing on the centroid. Normal stresses, generated by axial forces and bending moments, are either compressive or tensile and vary across the section from...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Combined Effects of Drugs: Synergism
Such synergistic combinations...

